Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma  by Scherpereel, Arnaud
ARTICLE IN PRESS
Respiratory Medicine (2007) 101, 1265–12760954-6111/$ - see fro
doi:10.1016/j.rmed.
$Funding source:
(Societe de Pneumo
Corresponding a
Hopital Calmette, C
Tel.: +33 3 20 44 49 9
E-mail address: a
1List of experts inGuidelines of the French Speaking Society for Chest
Medicine for management of malignant pleural
mesothelioma$
Arnaud Scherpereela,b,, French Speaking Society for Chest Medicine (SPLF)
Experts Group1aINSERM Unit 774, Institut Pasteur de Lille, France
bPulmonary and Thoracic Oncology Department, University Hospital of Lille, France
Received 29 June 2006; accepted 16 October 2006
Available online 29 November 2006KEYWORDS
Pleura;
Mesothelioma;
Guidelines;
Asbestosnt matter & 2006
2006.10.018
French Speaking
logie de Langue Fr
uthor. Clinique
HRU of Lille, 5903
8; fax: +33 3 20 44
-scherpereel@chr
Appendix.Summary
Previously considered as a rare tumor, malignant pleural mesothelioma (MPM) has become
a very important public health issue. In fact, MPM is a tumor with a poor survival, and its
incidence is expected to continue to increase for at least the next 10 years. Asbestos
exposure is the main factor involved in MPM pathogenesis. The diagnosis of MPM may be
difficult because of differential diagnosis such as pleural benign disease induced by
asbestos exposure or pleural metastasis of adenocarcinoma. Management of patients with
MPM also remains complicated because they are often referred for evaluation late in the
evolution of the disease. Moreover, MPM exhibits a high resistance to radiotherapy and
chemotherapy; only few patients are candidates for radical surgery. New therapeutic
strategies such as gene or cell therapy are still on clinical trial. Therefore, an optimal
treatment of MPM is not clearly defined yet, despite the introduction of recent drugs.
Between April 2005 and January 2006, the French Speaking Society for Chest Medicine
(SPLF), in collaboration with other French scientific societies, brought together experts on
mesothelioma to draw up recommendations in order to provide clinicians with clear,
concise, up-to-date guidelines on management of MPM, presented in this report.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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u-lille.fr.Introduction
Previously considered to be rare, malignant pleural me-
sothelioma (MPM) is a highly aggressive tumor that has
become a very important issue over recent years.1 Asbestos
exposure is the main factor involved in pathogenesis, which
can explain the rise in incidence of MPM since the 1960s.2
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in most other developed countries, the number of MPM
cases is expected to continue to rise for at least the
next 10 years. In addition, asbestos is still widely used in
many parts of the world, notably in emerging countries
such as China, India or Brazil, and in less-developed
nations.1 The diagnosis of MPM is difficult because the
disease may occur up to 30–40 years after asbestos
exposure, and the differential diagnosis on pleural biopsy
between MPM and pleural benign disease or metastasis of
adenocarcinoma may be difficult in some cases, even with
the use of immunohistochemistry.3 Since patients with MPM
have a poor outcome and an optimal treatment is not clearly
defined,4,5 MPM will remain a major public health problem
for many years.
In order to address this issue, the French Speaking
Society for Chest Medicine (SPLF), in collaboration with
the French Societies of Pathology (SFP), of Thoracic
and Cardiovascular Surgery (FSTCVS) and of Occupational
Medicine (SFMT), brought together experts on mesothelioma
from the four different Societies between April 2005
and January 2006 to draw up recommendations in
order to provide clinicians with clear, concise, up-to-
date guidelines on management of MPM. After a public
discussion during the 10th CPLF Meeting in Nice on 27
January 2006, these recommendations were first published
in French,6 then translated in the present publication.
The choice of an expert conference rather than a consensus
conference was made because of the limited amount of
information on mesothelioma currently available in
the literature. Practical questions relating to MPM were
raised by a scientific committee of the SPLF. A systematic
analysis of the literature was realised using the following
databases: Medline (National Library of Medicine, USA),Table 1 Official proposal for evidence-based medicine, provide
in order to give a grade to the recommendations by the experts
Scientific level of proof
Level 1
 Randomised comparative trials with high power
 Meta-analysis of randomised comparative trials
 Analysis of decision based on well-conducted studies
Level 2
 Randomised comparative trials with low power
 Non-randomised, well-conducted comparative studies
 Cohort studies
Level 3
 Case control studies
Level 4
 Comparative studies with significant bias
 Retrospective studies
 Case reports
 Observational studies (cross-sectional, longitudinal)Embase (Elsevier, Netherlands), Cochrane Library (Great
Britain), National Guideline Clearinghouse (USA), HTA
Database (International Network of Agencies for Health
Technology Assessment—INAHTA), BDSP (Public Health
Database, Rennes, France), NIH database (USA), Interna-
tional Pleural Mesothelioma Program—WHOLIS (WHO
Database). Each recommendation was graded by the
experts, based on the official proposal for evidence-
based medicine, provided by the French government’s
High Authority for Health (HAS) (see Table 1). Each
recommendation was voted by all experts: if less than 85%
of the experts were in total agreement with one proposal,
the corresponding recommendation was modified after a
new discussion.
These guidelines do not answer to all unresolved ques-
tions in the management of MPM. In fact, the literature is
really poor on many aspects of mesothelioma. In particular,
the question on the role of treatment of mesothelioma was
not perfectly addressed as there is no real publication
fully answering to this point yet.11 However, several studies
have shown that current doublets of chemotherapy can
improve the survival of MPM in comparison to single
monochemotherapy7,8 without altering the quality of life
of patients.9 Moreover, a small recent trial study was in
favour of an early use of chemotherapy to provide an
extended period of symptom control and a trend to survival
advantage.10
In conclusion, the Expert Conference organised by the
SPLF provided guidelines on MPM management for clinicians
and patients, including the latest diagnostic or thera-
peutic tools available in 2005. This Conference also aimed
at stimulate collaborations between the different
actors involved in MPM management, including research
laboratories.d by the French government’s High Authority for Health (HAS)
.
Recommendation grade
A. Established scientific proof
B. Scientific presumption
C. Low level of scientific proof
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evaluated and how is the at-risk population
identified?
Question 1.1: What are the risk factors associated
with malignant pleural mesothelioma (MPM), which
enable at-risk populations to be identified?
To date, two risk factors have been clearly established for
MPM: exposure to asbestos and to erionite. Other risk factors
for MPM have also been proposed, namely exposure to other
mineral fibres (particularly refractory ceramic fibres),
iodising radiation and SV40 virus. Tobacco exposure, on
the other hand, is known to not play a role in the
development of mesothelioma. It is widely accepted that asbestos is the main aetiolo-
gical agent of MPM. Although a dose–effect relationship
has been demonstrated, it has not been possible to
identify a threshold cumulative exposure level below
which there is no increased risk of developing the
disease. It is therefore recommended that individuals
who have been exposed to asbestos are targeted as the
main population at risk (A).
The risk of mesothelioma attributable to asbestos differs
markedly between men and women. To date, the reason for
this difference is unclear. It has been suggested that this
might result purely from inaccurate identification of
asbestos exposure, notably in situations of low and environ-
mental exposure. Further investigations into other potential aetiological
factors are recommended, particularly in females because
of their lower frequency of exposure to asbestos (A).
Genetic factors, which increase susceptibility, may con-
tribute to the development of mesothelioma. This hypoth-
esis is based essentially on the observation of familial cases
of mesothelioma. Nevertheless, no candidate gene has been
identified to date which predisposes an individual to
mesothelioma.
Question 1.2: What methods are available to
evaluate exposure to asbestos?
The probability of mesothelioma occurring after exposure to
asbestos depends on two factors: The time since the first asbestos exposure.
 The cumulative dose of asbestos, expressed as fibres/ml
air number of years of exposure. This formula takes
into account the number of episodes of exposure, each
episode being evaluated as the product of the mean
extent of exposure during the episode and the duration of
the episode.
Two methods can be used to estimate these two
parameters: occupational and environmental case histories,
and biometrology. In practice, it is important to define themethods used to evaluate exposure in the following three
circumstances: Compensation: in contrast to previous regulations,
current French regulations do not require exposure to
be determined in a precise manner. Screening: should only be carried out on individuals with
known exposure. Epidemiological studies: classification errors can lead to
either systematic bias (overestimation of exposure for
cases compared to controls), or a tendency to under-
estimate the real risk (errors equally distributed among
cases and controls).
The choice of tools for evaluating exposure will depend on
their precision and relevance for each type of study.
It is not possible to establish an exhaustive list of
occupations or work sectors associated with an increased
risk of MPM. Nevertheless, several occupations are clearly
associated with a reproducible relative risk greater than
two. This is the case, for example, for plumbers/pipe
fitters, electricians, carpenters–cabinetmakers and other
occupations in the construction industry. In addition, several
other work sectors have been associated with an increased
risk of mesothelioma in several studies. These include
shipyards, industries producing and manufacturing articles
made of asbestos and the construction industry in general.
However, the list of risk situations should not be restricted
to these occupations or work sectors. Although data in the
literature suggest that chrysotile asbestos and amphibole
asbestos may be associated with different degrees of pleural
carcinogenicity (the latter having higher potency), current
exposure questionnaires do not enable exposure to these
two types of fibres to be distinguished. Occupational and environmental anamnesis is the funda-
mental tool to determine exposure to asbestos. This has
to be used systematically for every patient with MPM (A). The advice of specialised consultations for Occupational
Medicine should be sought when exposure to asbestos is
not obvious (advice of experts). The occupational activity (sector of work and occupation)
considered to be the possible cause of exposure to
asbestos should figure systematically in the patient’s case
notes (advice of experts). The clinician should refer to the lists of work sectors,
occupations and occupational activities linked to asbes-
tos exposure to evaluate the importance of exposure (for
example: http://www.sante-securite.travail.gouv.fr/
mediatheque/pdf/medecin%20travail.pdf) (C).
Biometrology consists of the measure of asbestos (asbes-
tos bodies by optical microscopy, or asbestos fibres by
transmission electron microscopy, with analysis of chemical
elements) in biological specimens (lung tissue, bronchoal-
veolar lavage fluid, sputum). The technique enables
subjects with an abnormally high level of asbestos retention
in the respiratory tract to be identified and identifies
abnormal previous exposure, irrespective of its origin.
Carrying out biometrology (search for asbestos bodies in
biological specimens) is not an essential part of current
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with respect to MPM. However, biometrology (optical or
electron microscopy) is still useful for research and
aetiological studies (notably determination of the type of
asbestos retained).
Negative biometrology testing (a level of retention of
asbestos bodies seen by optical microscopy, or fibres
identified by electron microscopy, below thresholds for
abnormal retention with respect to the general population)
does not eliminate the possibility of sufficient exposure to
induce mesothelioma. From the viewpoint of identifying populations at risk for
mesothelioma, likely to be included in screening pro-
grammes, the only possible biometrology method is the
detection of asbestos bodies in sputum (advice of
experts). Nevertheless, it has not been demonstrated to date
whether biometric examination for asbestos bodies in
sputum provides additional information compared to
thorough anamnesis for the identification of exposure
to asbestos in the general population (advice of experts).
Question 1.3: Is there a place for screening for
mesothelioma? If so, what tools should be used?
For a screening programme to be justified, it is necessary
that detection of the disease can be followed by effective
intervention. It is also necessary to demonstrate the efficacy
and harmlessness of the screening programme, including all
the steps involved in early diagnosis and treatment in
identified patients (for interventions at the individual
patient level) and all prevention methods taken. As any
health-related procedure, the efficacy of a screening
programme is defined by a higher benefit/risk ratio for a
population undergoing screening than for a population not
being screened.
During a previous French consensus conference in 1999,
which focussed on the development of a clinical supervision
programme for individuals exposed to asbestos, the panel
concluded that the medico-social impact of screening for
mesothelioma should be evaluated.
Taking into account the data currently available on MPM
(prevalence, prognosis, therapy), and the performance
(sensitivity, specificity) of available screening methods
(thoracic imaging, biological markers), the value of a
screening from a medical and public health viewpoint has
not been demonstrated to date.
Two types of approach can be considered: thoracic
imagery and biological markers. Chest conventional radiograph has low sensitivity for the
detection of weak or moderate pleural effusions Ultra-sound is a simple and sensitive technique to detect
pleural effusion but does not offer complete assessment
of the pleural cavity Pleural effusion and pleural thickening are the two signs
which can suggest the presence of mesothelioma on chest
computed tomography scanning (CT scan) Magnetic resonance imaging (MRI) and [18F]-fluorodeox-
yglucose positron emission tomography (PET) are cur-rently not used as screening techniques, due to their high
cost and limited availability.
Post-occupational monitoring, which has been proposed
for individuals with previous exposure to asbestos, will
increasingly include an initial chest CT scan starting
at 50 years of age, using a standardised protocol for
examination and interpretation. If pleural effusion is
identified with CT scan, a systematic diagnostic procedure
can be proposed, consisting of thorascopy with pleural
biopsies. In contrast, complementary strategies for investi-
gating pleural thickening identified on CT scan have not yet
been validated. When an abnormality is identified by CT scan, it is
important that an additional diagnostic strategy of
investigation be proposed and evaluated in order to
determine the value of biological markers, PET, MRI and
the frequency of these examinations (A).
The value of using serological markers for proliferation of
tumoral mesothelial cells is being reinvestigated, following
the recent demonstration of an increase in levels of soluble
mesothelin-related peptides (SMRP) or osteopontin in the
serum of patients with MPM. Nevertheless, the amount of
data available is limited and does not yet permit satisfactory
evaluation of the sensitivity (as a function of cell differ-
entiation and proliferation) or specificity (presence or
absence of the marker in other cancers). The value of these
markers for screening should be separated from their
potential value in initial diagnosis and/or monitoring the
outcome of mesothelioma. The performance of biological markers of MPM has not
been evaluated sufficiently to date. Therefore, it is
recommended that such biological markers should not be
used for screening for MPM, even in populations exposed
to asbestos, outside specific research programmes (A).
Question 2: What are the diagnostic criteria for
MPM?
2.1. Diagnostic methods
Question 2.1.1: Are there any clinical diagnostic criteria?
The clinical manifestations of MPM are not specific
and usually appear late at an advanced stage in the course
of the tumour. Clinical signs suggesting a diagnosis of MPM
include chest pain, thoracic retraction or a unilateral
thoracic mass in patient with a past history of asbestos
exposure. It is recommended to not base a diagnosis of MPM on
clinical criteria (A).
Question 2.1.2: Are there any imaging criteria for MPM
diagnosis?
Conventional chest radiograph is only abnormal in the
advanced stages of MPM with, in the majority of cases, a
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is relatively cheap but its diagnostic accuracy (sensitivity,
specificity) is poor. It is recommended to not use chest radiograph to assess a
diagnosis of MPM (A).
Chest high-resolution CT scan is a key imaging procedure
for the diagnosis of MPM. It is unable for definitive diagnosis,
but certain features, such as the presence of pleural diffuse
thickening or mass with thickening of interlobular fissures,
are highly suggestive of MPM. However, the value of CT scan
in patients with an abundant pleural effusion is poor (non-
specific feature). CT scan is also relevant, before a
thoracoscopy, for the evaluation of tumour extension to
the chest wall, pericardium, diaphragm, mediastinal struc-
tures or locoregional lymph nodes, and the detection of
infra-diaphragmatic invasion or metastases. CT scan is the
cornerstone for longitudinal follow-up of patients. It is recommended that follow-up be carried out, after
removal of pleural effusion, by a chest and abdominal
multidetector (MD) CT scan with multiplaner reforma-
tion, for diagnosis and staging of MPM (A).
In contrast to CT scan, MRI is not systematically
performed. Although MRI is not relevant for the diagnosis
of mesothelioma, it can be helpful for the determination of
the extent of the tumor to the local organs (diaphragm,
mediastinum, chest wall). This technique is usually reserved
for patients who are candidates for radical surgery. The
diagnostic performance of MRI for the determination of the
tumor extension is considered to be better compared to CT
scan. Nevertheless, no study to date has assessed the
effectiveness of MD CT scan for the MPM staging. Compara-
tive studies during surgery revealed the limits of MRI for the
disease staging. In particular, as for CT scan, the N and T
stage disease can be underestimated in patients undergoing
surgery. It is recommended that thoracic MRI is not systematically
performed for the diagnosis of MPM (C).
(PET usually shows a hypermetabolism of pleural me-
sothelioma, metastatic adenopathy and metastasis. The
diagnostic relevance of these features is considered as poor.
The place of PETcombined with CT scan and its exact role in
the diagnosis of MPM are unknown.
It is recommended that PET is not performed system-
atically for the diagnosis of MPM (advice of experts).
However, the value of PET combined with CT scan in the
diagnosis of MPM requires further evaluation.
Question 2.1.3: Are there any diagnostic criteria linked to
the analysis of pleural fluid?
Examination of pleural fluid is insufficient for the unequi-
vocal diagnosis of MPM. No discriminant pleural fluid marker
(such as hyaluronic acid) has been yet established. Never-
theless, the value of the level of SMRP and osteopontin
measured in the pleural fluid should be evaluated. It is recommended to not base a diagnosis of MPM on the
analysis of soluble markers in the pleural fluid (A).
Question 2.1.4: What is the place of transparietal
biopsies? Transparietal biopsies with or without CT scan or ultra-
sound guidance are not recommended for the diagnosis of
MPM except in patients for whom thoracoscopy is contra-
indicated (A).
Question 2.1.5: What is the place of lymph node biopsies?
Histopathology can be confusing between MPM and lympha-
tic drainage of normal mesothelial cells originating from an
effusion. In a few cases, a diagnosis of MPM can be obtained
by a biopsy of superficial adenopathy, but it is crucial to seek
the advice of a panel of experts. It is recommended to not base a diagnosis of MPM on
lymph node biopsies without validation by a panel of
experts in pathology (A).
Question 2.1.6: Are there any biological diagnostic
markers of MPM?
No tumor marker (including hyaluronic acid) can currently
be considered reliable. The level of SMRP in blood or pleural
fluid appears promising, since SMRP levels appear to
correlate with tumor mass. However, the value of SMRP
and osteopontin in the diagnosis of MPM requires further
evaluation. It is recommended to not use the level of pleural
hyaluronic acid for the diagnosis of MPM, but further
research on new soluble markers such as SMRP and
osteopontin should be carried out in order to determine
their role in the diagnosis of MPM (A).
Question 2.1.7: What is the role of thoracoscopy in the
diagnosis of MPM?
Thoracoscopy is the best method to obtain the diagnosis of
MPM when suspected on clinical or radiological data.
Diagnostic accuracy is greater than 90% and complications
occur in less than 10% of cases. Fibrohyaline pleural plaques
are benign. In case of non-specific pleural lesions, biopsies
should be performed on the parietal pleura around the
plaques and in pleural zones ‘‘marked’’ by anthracosis. It is recommended, except in case of preoperative
contraindication or pleural symphysis, to perform thor-
acoscopy for the diagnosis of MPM (A).
Question 2.1.8: What is the role of thoracotomy
procedure in the diagnosis of MPM?
Direct access to the pleura by minimally invasive thoracot-
omy enables tissue biopsies to be obtained for pathological
examination, notably in the absence of pleural effusion. This technique should be reserved for cases with
potential pleural symphysis leading the failure of
thoracoscopy procedure (A).
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which arises from mesothelial cells that line the serosal
cavities, is made on histopathological examination. How-
ever, diagnosis can be extremely difficult because mesothe-
lioma can show various misleading histopathological pitfalls,
and pleura is a common site for metastatic disease.
Macroscopic appearance of mesothelioma depends of
when in its natural history the tumor is first observed. As
mesothelioma grows, the gross appearance is suggestive of
MPM to some extent, although other malignant tumours
(thymomas, carcinomas, lymphomas, angiosarcomas) can
appear with a pseudomesotheliomatous aspect. The micro-
scopic appearances of MPM are well defined in the
international classification of pleural tumours.11 However,
this tumor has varied and deceptive appearance in a high
percentage of cases and may resemble benign pleural
lesions or metastatic lesions.
Pleural metastases are much more common than me-
sothelioma: 150 000 pleural metastatic lesions are recorded
each year in the USA (compared with 1/50 cases of
mesothelioma). The most frequent primary cancers invol-
ving pleural metastatis are lung and breast carcinomas
whose morphology can be mistaken for mesothelioma on
standard sections stained with haematoxylin–eosin–saffron
(in 7–15% and 7–11%, respectively).
Diagnostic problems also occur with benign inflammatory
or reactive lesions of the pleura. These very frequent lesions
occur often in patients of the same age group as
mesothelioma (pleural effusion during cardiac failure,
collagen disease, pneumonia or cirrhosis; they may lead to
atypical mesothelial hyperplasia which can result in diag-
nostic error. In the French National Program of Mesothelioma
Survey (1998–2007) experience, such errors represent 13% of
initially diagnosed cases.
The quality of diagnosis will improve with time, due to a
better understanding of the pathology by clinicians,
particularly pneumonologists and pathologists, and progress
in development of histopathological diagnostic techniques.
Question 2.2.1: Which specimens for which clinical
presentation?
As pleural effusion is usually the first clinical sign of MPM,
cytology is often the first diagnostic examination to be
carried out. It is recommended to not make a diagnosis of mesothe-
lioma based on cytology alone because of the high risk of
diagnostic error (A).
Diagnosis of mesothelioma from fine needle biopsies
(Abrams or Castelain needles) is associated with the same
problems as cytology. A conclusive diagnosis can only be
made if the material is representative of the tumor and in
sufficient quantity to allow immunohistochemical charac-
terisation. Fine needle biopsies are not recommended for
the diagnosis of mesothelioma because they are
associated with low sensitivity (around 30%). Thoraco-scopy is preferred, allowing a diagnosis in more than 90%
of cases (A). In the presence of fibrohyaline plaques, it is recom-
mended that biopsies are taken from the edge of the
plaque at the time of thoracoscopy (advice of experts). Faced with uniformly thick pleura, complete visual
examination of the pleura is recommended, necessitating
biopsies in the form of pleural scrapes (advice of
experts). It is recommended that a diagnosis of MPM is not made on
frozen tissue sections (A).
Question 2.2.2: What classification should be used? It is recommended that the WHO 2004 classification be
used for mesothelial tumours, which provides a compara-
tive basis for diagnosis, prognosis and patient manage-
ment (A).
Question 2.2.3: Should a complementary
immunohistochemical examination be carried out in
addition to morphological examination? If so, when?
Which immunohistochemical markers should be used for
which histological variants? How many antibodies should
be used? It is recommended that a diagnosis of MPM always be
based on immunohistochemical examination (A). In full accordance withe the International Mesothelioma
Panel, it is recommended to use two markers with
positive diagnostic value for mesothelioma (nuclear
markers such as anti-calretinin and anti-WT1 or the
membrane marker anti-EMA, or for epithelioid mesothe-
lioma, anti-CK5/6) and two markers with negative
diagnostic value (anti-Ber-EP4, a membrane marker;
anti-TTF1, a nuclear marker; monoclonal anti-CEA,
anti-B72-3, anti-ER/PR, anti-EMA, cytoplasmic staining)
to validate the diagnosis (A). For sarcomatoid forms, it is recommended to use two
broad-spectrum anti-cytokeratin antibodies; negative
immunostaining with a single antibody does not exclude
the diagnosis (advice of experts), and two markers
with negative predictive value (such as anti-CD34 and
anti-BCL2, anti-desmin, anti-S100) to confirm the
diagnosis (A).
For atypical mesothelial hyperplasia’s (superficial me-
sothelial proliferations), there are currently no commer-
cially available immunohistochemical markers which may
indicate the benign or malignant nature of the cells.
Question 2.2.4: Should electron microscopic examination
be performed? When should this type of examination be
performed? Electron microscopy is a laborious examination and
should not be routinely performed to confirm the
diagnosis of mesothelioma. On the other hand, this
technique is of value for epithelial tumours when
immunohistochemical results are discordant, and in some
sarcomatoid tumours. Moreover, it is not ultrastructurally
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mesothelial cells. The presence of long, thin microvilli is
highly suggestive of mesothelioma (A).
Question 2.2.5: What is the role of molecular biology?
When should it be performed and what types of analysis
are required? Should specimens need to be systematically
frozen for a tissue bank? There are no diagnostic or therapeutic reasons for
freezing pleural tumor tissue. In contrast, it is recom-
mended that tissue material should be frozen for
research purposes, to increase our knowledge of this
disease (predictive markers of progression, markers of
resistance to chemotherapy, discovery of therapeutic
targets) (A).
Question 2.2.6: Should the advice of a panel of experts be
sought faced with a suspicion of MPM? It is recommended that a pathologists’ panel (the
‘‘Mesopath’’ panel in France) is asked to confirm the
diagnosis for patients included in randomised therapeutic
trials, or in any case where there is doubt about the
diagnosis (advice of experts).
Question 3: What pre-therapeutic assessment
should be proposed for a patient with MPM?
Question 3.1: What assessment is necessary in a
patient newly diagnosed with MPM at the time of
initial management? It is recommended that a minimum assessment should
include a clinical examination, a chest X-ray, a thoraco-
abdominal CT scan with injection of contrast material
(after removal of pleural fluid), a thoracoscopy with a
standardised report, and a histopathological examination
to precise the pathological subtype of MPM (A). For research purposes, this assessment should also include
biological prognostic markers (SMRP, osteopontin) (B).
Question 3.2: What additional non-invasive tests
should be performed if an extrapleural
pneumonectomy (EPP) is indicated? It is recommended that the pre-therapeutic assessment is
completed with a chest MRI (facultative), a PET coupled
with CT scan (PET-CT scan), a lung function study, a
pulmonary scintigraphy, and a cardiac ultra-sound (B).
Question 3.3: Which additional invasive
examinations should be discussed before surgery if
an EPP is indicated? Systematic contralateral thoracoscopy and laparoscopy
are not recommended. An extent of MPM to the
extrapleural lymph nodes is a contraindication for EPP.Mediastinoscopy is recommended if CT scan or PET
suggest an extent to mediastinal lymph nodes (advice
of experts).
Question 3.4: Should talc pleurodesis be
systematically performed at the time of
thoracoscopy? It is recommended not to systematically perform talc
pleurodesis at the time of diagnostic thoracoscopy.
However, talc pleurodesis should be considered as
part of the overall therapeutic plan proposed for the
patient:
o If the subject is very old or if no active treatment is
planned, talc pleurodesis should be performed (advice
of experts).
o If EPP may be indicated for the stage of the disease, it
is possible to perform talc pleurodesis if the operator
is certain that this will not hinder recovery of biopsy
samples for histological diagnosis. Thus, it is recom-
mended not to perform talc pleurodesis if the
macroscopic aspect of the pleura is not evocative of
a malignant lesion, so that a second examination can
be performed if necessary without being hampered by
pleural symphysis (advice of experts).Question 3.5: How can the prognosis of a patient
with MPM be evaluated? What is the value of
prognostic factors in clinical practice?
The loco-regional extent of the disease is an important
determinant of prognosis, with a significant survival
benefit in case of early disease identified by thoracoscopy
(stage Ia), or the absence of mediastinal lymph node
invasion.
Besides the Tand N criteria, other prognostic factors have
been validated (CALGB/ EORTC), including demographic
(sex, weight, age), clinical (performance status) or biologi-
cal (histology, haemogram, inflammatory syndrome, LDH)
variables.
Other prognostic factors have been reported that require
further evaluation. These include tumor hypermetabolism
measured by PET or biological markers such as SMRP. It is recommended that prognostic factors not be used on
an individual level in daily practice. However, it is
recommended that these prognostic factors are used in
clinical research because they can contribute to the
classification of patients into homogenous groups and
facilitate comparison of results between studies (B).
Question 3.6: How can the stage of MPM be
determined? What are the limitations and
disadvantages of the classifications currently
available?
Since 1995, the International Mesothelioma Interest Group
(IMIG) classification, based on CT Scan, is the most
frequently used classification.
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dated with patients who have been surgically treated, it
is recommended to use the IMIG classification until a new
system of classification better adapted to MPM has been
set up (B).
Question 4: What is the therapeutic strategy in
MPM?
Question 4.1: What is the role of surgery?
Question 4.1.1: What are the recommendations for
surgery in MPM? A large postero-lateral thoracotomy usually through the
6th intercostal space is the recommended thoracic
incision. The 6th rib can be resected to provide an
adequate exposure (advice of experts).
Pleurectomy involves removal of the whole parietal,
diaphragmatic and mediastinal pleura. Except in early stage
of the disease (IA), pleurectomy is a palliative procedure. It is recommended that pleurectomy should not be
performed in other disease stages than stage IA (advice
of experts).
Pleurectomy-decortication (P/D) associates pleurectomy
with visceral decortication, and entails resection of
involved visceral pleural surface with preservation of lung
parenchyma. P/D is considered as a palliative procedure. Therefore it
is not a recommended surgical procedure for MPM (advice
of experts).
Extra-pleural pleuropneumonectomy (EPP) includes the
‘‘en-block’’ removal of the pleura, pericardium, diaphragm,
and the whole lung involved with the tumor. It is
recommended to perform EPP by monoblock including
resection of the diaphragmatic cupula for carcinological
reasons. EPP is the only surgical procedure for MPM (except for
stage IA) able to lead to a carcinological resection in
selected patients, included in randomised clinical trials
(advice of experts).
Question 4.1.2: What therapeutic strategy should be used
for MPM? Regardless of the therapeutic strategy envisaged, surgi-
cal treatment of MPM should only be considered as part of
a multidisciplinary approach to management (A). It is recommended that surgical treatment of MPM be
performed in a reference centre able to offer both a
surgical team trained in this kind of surgery and a
pulmonary-oncologist medical team (A).Question 4.2: What is the role of chemotherapy?Question 4.2.1: Has the benefit of chemotherapy been
demonstrated?
First-line chemotherapy with a combination of cisplatin/
pemetrexed or cisplatin/raltitrexed has been demonstrated
to be more beneficial than monochemotherapy. No rando-
mised study has demonstrated the benefit of second-line
chemotherapy on survival or quality of life after failure of
primary chemotherapy. It is recommended that patients in a good performance
status (PS) be included in clinical trials, this approach
being ethically acceptable (A).
Question 4.2.2: Which patients are likely to benefit from
chemotherapy?
Patients older than 18 years of age, in a good PS (0 or 1) are
likely to benefit from chemotherapy. The indications depend
on comorbidities (cardiovascular, renal, pulmonary diseases)
and the wishes of the patient and his family. The indication for chemotherapy should be discussed on a
case-by-case basis in a multidisciplinary meeting (A).
Question 4.2.3: When should chemotherapy be started?
For how long should chemotherapy be continued?
The available arguments in the literature, in favour of
initiating chemotherapy as soon as a diagnosis is made, are
weak and indirect. It is nevertheless recommended that administration of
chemotherapy not be delayed and not to wait for the
appearance of functional signs (C). It is recommended that chemotherapy be stopped in
cases of progressive disease, grades 3–4 toxicities, or
cumulative toxic doses (A), and after six cycles in
patients who respond or are stable (C).
Question 4.2.4: What cytotoxic drugs are effective? As
first-line treatment? As second-line treatment? The association of cisplatin and an antimetabolite
(pemetrexed or raltitrexed) is recommended as first-line
chemotherapy (A). No chemotherapy can be recommended as second-line
after failure of chemotherapy including cisplatin. For
patients who have not been given first-line treatment
including cisplatin, cisplatin-based chemotherapy can be
proposed (advice of experts).
Question 4.2.5: What is the role of biotherapies in the
treatment of MPM? The role of immunomodulating agents is unknown and it
is recommended that they not be used in the treatment
of MPM outside clinical trials (A). Likewise, current data
do not support intrapleural administration of immuno-
modulators outside clinical trials. To date, no targeted biotherapy has been demonstrated
to be effective in MPM. It is recommended that trials be
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administration (B).
Question 4.2.6: What assessment criteria are used to
determine the efficacy of these drugs? It is recommended that overall survival be used as the
primary outcome for evaluating the efficacy of che-
motherapy in clinical trials (A). For assessment and follow-up of MPM, chest CT scan is
recommended (A). When a patient has been treated
for a pleural symphysis, it is recommended that
chest CT scan be performed before the start of
chemotherapy in order to better evaluate the response
to chemotherapy (A). It is recommended that one of the following evaluation
methods be used in clinical trials, depending on
the appearance of the target lesion: WHO for bidimen-
sional lesions, RECIST for unidimensional lesions, and
modified RECIST in the case of circumferential pleural
lesions (C). The role of PET or PET combined with CT scan in
assessment of the response to chemotherapy requires
evaluation; this approach means that a reference PET
must be performed before any chemotherapy (C).
No biological marker has been validated to date for the
evaluation of response to anti-tumor treatment in MPM. It is therefore recommended not to rely on the level of
any one particular biological marker to evaluate treat-
ment response (A). It is recommended that quality of life and symptoms
during chemotherapy be evaluated to appreciate the
clinical benefit (efficacy/tolerability) for diseases with a
poor prognosis and for which the impact of treatment on
survival has not been demonstrated clearly or is only
marginal (A). No particular scale of quality of life is
recommended on an individual level.
Question 4.3: What is the role of radiotherapy in
MPM?
Question 4.3.1: What is the role of ‘‘palliative’’
radiotherapy aimed at pain relief? Palliative radiotherapy aimed at pain relief is recom-
mended in cases of painful parietal infiltration by MPM or
subcutaneous metastasis (B).
Question 4.3.2: What is the role of radiotherapy in the
prevention of parietal seeding along the drainage
channels? It is recommended that irradiation with 3 7Gy for three
consecutive days, in the 4 weeks following drainage or
thorascopy, be performed to prevent subcutaneous
metastasis developing along drainage channels or thor-
acocentis tracts, using electrons with an energy adapted
for depth (A) and a cutaneous bolus. To limit the risk of seeding along procedure tracts,
it is recommended that pleural puncture be avoided,
whenever possible, in cases where pleural effusion occurs
in an individual known to be professionally exposed to
asbestos. In those cases, primary thorascopy should be
used in preference. Puncture points or thoracoscopic
scars should be marked systematically for early irradia-
tion as soon as the diagnosis is confirmed (advice of
experts).
Question 4.3.3: What is the role of post-operative
radiotherapy? Data from the literature are limited; however, it is not
recommended that radiotherapy on large fields be
performed after pleurectomy or decortication (C). In the absence of phase III randomised trials, the
establishment of a prospective controlled study evaluat-
ing the efficacy and tolerability of adjuvant radiotherapy
post-EPP (minimum dose of 50 Gy) is recommended (C). The technique of post-operative irradiation after EPP is
complicated. It is therefore recommended to perform
this in specialised centres (advice of experts).
Question 4.3.4: What is the place for intensity-modulated
radiotherapy (IMRT) in MPM after EPP?
IMRT is of interest in this indication, but should be the
subject of complementary studies. It is not recommended to use IMRT after EPP in MPM,
outside clinical research studies (advice of experts).
Question 4.4: Therapeutic indications for a
multimodal approach to MPM.
Question 4.4.1: What is the place for pleurectomy or
pleurectomy/decortication (P/D)?
In contrast to P/D, which is not recommended as it
is not carcinologically valuable (see Question 4.1), pleur-
ectomy has a role in the early stage of MPM (Ia). Never-
theless, comparative studies with other therapeutic
strategies have not been done. This surgery is used at a
stage of the disease when the natural history without
treatment is unknown, and can be spontaneously long.
It is difficult to realise a randomised clinical trial as
this condition is very rare, making any recommendation
impossible.
Likewise, in the more advanced stages, no randomised
trial has compared decortication with EPP, or has evaluated
the role of adjuvant treatment. No recommendation can
therefore be given.
Question 4.4.2: What is the place for extra-pleural
pneumonectomy (EPP)? It is recommended that EPP be performed in specialised
centres used to this kind of radical surgery, as part of a
multidisciplinary approach with adjuvant (radiotherapy)
or neoadjuvant (chemotherapy) treatment (C).
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morbidity and mortality, offers a survival benefit (on
average 17 to 23 months). EPP can benefit only a select
population (around 10% in total) for whom spontaneous
survival is unknown in the absence of clinical trials
comparing radical surgery with no surgery.
The feasibility of a multimodal approach should be
proven (neoadjuvant chemotherapy with the reference
protocol, cisplatin-pemetrexed) followed by EPP and
post-operative radiotherapy (a single publication has re-
ported the results of a pilot trial of 19 patients; several
trials are currently underway). It is necessary to
randomise patients to either surgery (MARS protocol in
Great Britain) or radiotherapy (SAKK protocol in Switzer-
land) and chemotherapy. In addition to toxicity criteria
(mortality and morbidity), it is necessary to evaluate quality
of life. In the absence of results from these feasibility studies or
randomised trials, it is recommended to perform this
type of surgery only in clinical trials (A).
Question 5: What methods are used to control
symptoms and quality of life in MPM?
Question 5.1: Management of pain
MPM is associated with pain initially due to excessive
nociception. Much later in the disease process, neurogenic
pain (neuropathological) may arise due to invasion of
nervous structures or as a side effect of therapy.Question 5.1.1: How is pain in MPM evaluated?
Chest pain is a frequent symptom of MPM. It becomes more
and more disabling and refractory to analgesic treatment as
the tumor growths. This is considered to be ‘‘disease-pain’’. In a patient able to communicate, a visual analogue scale
is recommended to measure the evolution of cancer pain
in MPM (A). In a patient who is confused and in pain due to
progression of mesothelioma, a behavioural assessment
analogous to the Doloplus scale can be used (C).
Question 5.1.2: What are the general principles of
treatment of nociceptive pain related to MPM?
The World Health Organisation and various professional
medical associations have established guidelines for cancer
pain relief. Pain related to mesothelioma: Should be managed as cancer pain in general (B).
 Can be controlled in around 90% of cases by oral
treatments. However, neurosurgical techniques can be
performed, but decisions should be taken solely by a
multidisciplinary team experienced in pain management
in general and in these techniques in particular and after
careful evaluation of the benefit/risk ratio for each
indication (B).Question 5.2: Management of dyspnoea?Dyspnoea is a common symptom in patients with MPM.
In the majority of cases, dyspnoea is in relation with a
pleural effusion, which is usually recurrent. Therefore,
control of pleural effusion is the main treatment for
dyspnoea in MPM.
Question 5.2.1: Is repetition of pleural puncture for
drainage justified?
Repeated thoracentesis increase the risk of malignant
seeding along of the puncture tracts, leading to the
appearance of subcutaneous metastasis. It is recommended that repeated therapeutic thoracentesis
not be performed in MPM, in order to avoid the repetition
of prophylactic radiotherapy (advice of experts).
Question 5.2.2: What is the place of talc pleurodesis? Talc pleurodesis by thorascopy (talc poudrage) is the
method of choice for the management of recurrent
pleural effusion in a patient with MPM (B). Talc slurry is also an effective pleurodesis method.
However, it is recommended that this technique is
reserved for patients with poor performance status or
with a limited life expectancy (advice of experts).
Question 5.2.3: When should talc pleurodesis be
performed? It is recommended that talc pleurodesis is early
performed, if it does not compromise the oncological
therapeutic strategy (advice of experts).
Question 5.2.4: Are other local treatments of value in the
management of dyspnoea? In case of failure of talc poudrage and for patients with
poor performance status or with a limited life expec-
tancy, insertion of a chronic indwelling pleural catheter is
recommended (C). It is recommended that a pleuro-peritoneal shunt not be
used because of the high risk of complications and the
poor efficacy of this technique (C).
Question 5.2.5: Do systemic anti-cancer treatments have
an effect on dyspnoea? The choice of chemotherapy can be based, at least in
part, on the objective of relieving dyspnoea, insofar as
this treatment can improve respiratory symptoms (C).
Question 5.2.6: Can other measures be used to alleviate
dyspnoea?
No study has been performed to evaluate oxygen therapy
in MPM. However, the prescription of long-duration
oxygen therapy may be considered in current clinical
practice in order to improve the comfort of a patient with
hypoxaemia.
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effective in terms of improvement of dyspnoea, it is
recommended that they be used preferentially in
dyspnoeic patients with severe pain (advice of experts). In the absence of evidence, it is not recommended that
systemic or inhaled corticotherapy be prescribed against
dyspnoea (advice of experts). It is recommended that the emotional and psychological
components of dyspnoea be systematically managed
(advice of experts).
Question 6: Medico-social aspects in MPM?
Question 6.1: What medico-social approaches are
possible?
In France, a diagnosis of MPM gives the patient a right to one
or several medico-social benefits: Obtaining recognition of an occupational disease status,
in the case of occupational asbestos exposure. Medical management with compensation from the
‘‘Fonds d’Indemnisation des Victimes de l’Amiante
(FIVA)’’, a national compensation fund for victims of
asbestos devoted to help patients with asbestos-related
diseases, in addition or in replacement of a compensation
for a recognised occupational exposure. For the FIVA,
MPM is a disease considered as presumption of previous
exposure to asbestos and therefore compensated. The right to benefit from early retirement (from the age
of 50 years).
Question 6.2: Why is a medico-social approach
proposed?
A medico-social approach is appropriate because the
diagnosis of MPM involves both collective and individual
consequences and responsibilities.
Question 6.3: How to proceed with different
medico-social approaches?
Social services should be informed of an occupa-
tional disease by the patient provided with a medical
certificate.
For MPM, it is important that an immunohistochemical
analysis is available on pleural biopsies before requesting
recognition of an occupational disease or when making a
request for compensation from FIVA. In routine practice, it is
desirable that cases are reassessed and confirmed histolo-
gically by a panel of pathology experts if there is any doubt
about the diagnosis.
Question 6.4: What is the role of the pulmonary
physician in the medico-social field for a patient
with MPM? In the case of probable or definite occupational exposure
to asbestos identified by questioning, a medical certifi-cate should be issued and given to the patient mentioning
the disease and its possible link with previous occupa-
tional exposure (A). A request for compensation from FIVA should be proposed
in France for all patients (or their eligible representa-
tives), whether exposure to asbestos has been identified
or not, and whatever the source of that exposure (A).
Appendix. List of the French experts of the
SPLF Conference on MPM
Notice: The full list of the references used by the experts
may be found in: ‘‘Recommandations de la Socie´te´ de
Pneumologie de Langue Franc-aise (SPLF) sur le Me´sothe-
liome pleural—Confe´rence d’experts’’ (full text). Rev Mal
Respir 2006 (Special ed. in press). Copyright SPLF, Paris
2006, all rights reserved.
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(Lyon), T. Berghmans (Bruxelles, Belgique), G. Bonardel
(Paris), J.M. Brechot (Bobigny), P. Brochard (Bordeaux),
M.C. Copin (Lille), B. Crestani (Paris), G. Dabouis (Nantes),
A.Y. Delajartre (Nantes), M. Derzelle (Reims), Fournier
(Clichy), A. Fraticelli (Marseille), F. Galateau-Salle (Caen),
R. Giudicelli (Marseille), P. Godard (Montpellier), F. Grassin
(Brest), M. Gregoire (Nantes), L. Greillier (Marseille), D
Grunenwald (Paris), J. Guigay (Villejuif), C. Hennequin
(Paris), B. Housset (Cre´teil), M.C. Jaurand (Paris), K. Kerrou
(Paris), Y. Lajat (Nantes), F. Laurent (Bordeaux), F. Le
Pimpec-Barthes (Paris), C. Le Pechoux (Villejuif), D. Lerouge
(Caen), J. Margery (Metz), C.-H. Marquette (Lille), O.
Menard (Nancy), JL. Michaud (Nantes), I. Monnet (Cre´teil),
J.F. Morere (Bobigny), F. Natali (Brest), J.-C. Meurice
(Poitiers), J.C. Pairon (Cre´teil), M. Perol (Lyon), H. Porte
(Lille), P. Poulain (Paris), G. Robinet (Brest), P. Ruffie
(Villejuif), R. Salmi (Bordeaux), A. Scherpereel (Lille), S.
Trogrlic (Nantes), J.M. Vignaud (Nancy), V. Westeel (Besanc-
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